These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22752616)

  • 1. The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes.
    Behr ER; January C; Schulze-Bahr E; Grace AA; Kääb S; Fiszman M; Gathers S; Buckman S; Youssef A; Pirmohamed M; Roden D
    Eur Heart J; 2013 Jul; 34(26):1958-63. PubMed ID: 22752616
    [No Abstract]   [Full Text] [Related]  

  • 2. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
    Pirmohamed M; Aithal GP; Behr E; Daly A; Roden D
    Clin Pharmacol Ther; 2011 Jun; 89(6):784-5. PubMed ID: 21593754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
    Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
    Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular basis of drug-induced torsades de pointes.
    Roden DM
    Br J Pharmacol; 2008 Aug; 154(7):1502-7. PubMed ID: 18552874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk management of QT-prolonging drugs by community pharmacists using a mobile electrocardiograph].
    Shinozaki K
    Yakugaku Zasshi; 2010 Nov; 130(11):1597-601. PubMed ID: 21048421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.
    Cubeddu LX
    Am J Ther; 2003; 10(6):452-7. PubMed ID: 14624285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced long QT syndrome in women.
    Li G; Cheng G; Wu J; Zhou X; Liu P; Sun C
    Adv Ther; 2013 Sep; 30(9):793-802. PubMed ID: 24085659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding drug-induced torsades de pointes: a genetic stance.
    Kannankeril PJ
    Expert Opin Drug Saf; 2008 May; 7(3):231-9. PubMed ID: 18462182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project.
    Hazell L; Raschi E; De Ponti F; Thomas SH; Salvo F; Ahlberg Helgee E; Boyer S; Sturkenboom M; Shakir S
    J Clin Pharmacol; 2017 May; 57(5):558-572. PubMed ID: 28019033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Torsades de pointes from terfenadine and sotalol given in combination.
    Feroze H; Suri R; Silverman DI
    Pacing Clin Electrophysiol; 1996 Oct; 19(10):1519-21. PubMed ID: 8904547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does subclinical hypothyroidism explain the increased susceptibility of women to torsades de pointes?
    Lehmann MH; Frankovich D; Baga JJ; Pires LA; Schuger CD; Steinman RT; Rabinowe SL
    Am J Cardiol; 1997 Apr; 79(7):963-5. PubMed ID: 9104914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced arrhythmia: pharmacogenomic prescribing?
    Behr ER; Roden D
    Eur Heart J; 2013 Jan; 34(2):89-95. PubMed ID: 23091201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM
    J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.
    Shaffer D; Singer S; Korvick J; Honig P
    Clin Infect Dis; 2002 Jul; 35(2):197-200. PubMed ID: 12087527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding torsade de pointes: a bridge to tailored drug therapy?
    Tan HL; Wilde AA
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):87-8. PubMed ID: 12090899
    [No Abstract]   [Full Text] [Related]  

  • 16. Torsades de pointes with Almokalant, a new class III antiarrhythmic drug.
    Wiesfeld AC; Crijns HJ; Bergstrand RH; Almgren O; Hillege HL; Lie KI
    Am Heart J; 1993 Oct; 126(4):1008-11. PubMed ID: 8213422
    [No Abstract]   [Full Text] [Related]  

  • 17. Torsades de pointes associated with fluoroquinolones.
    Owens RC; Ambrose PG
    Pharmacotherapy; 2002 May; 22(5):663-8; discussion 668-72. PubMed ID: 12013370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing predictors of drug-induced torsade de pointes.
    Belardinelli L; Antzelevitch C; Vos MA
    Trends Pharmacol Sci; 2003 Dec; 24(12):619-25. PubMed ID: 14654302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.
    Kounas SP; Letsas KP; Sideris A; Efraimidis M; Kardaras F
    Pacing Clin Electrophysiol; 2005 May; 28(5):472-3. PubMed ID: 15869686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of torsades de pointes caused by sotalol therapy.
    Cammu G; Geelen P; Baetens P; De Vos J; Demeyer I
    Resuscitation; 1999 Jan; 40(1):49-51. PubMed ID: 10321848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.